A French leading newspaper, Le Parisien, has featured an article on the PolarCap® System, highlighting PolarCool´s current presence in the Top 14 league and its potential impact on the French market.
The article is framed in a positive response to PolarCool’s recent two-year agreement with Stade Français for the use of the PolarCap® System, as well as the company´s evaluation agreements with Biarritz Olympic and Clermont Auvergne. Dr Elliot Rubio, team doctor of Stade Francais, speaks positively in regard to his experiences with using the device on players that have sustained a concussion, as does Dr Remi Gaulmin, team doctor of Clermont Auvergne.
It is also proposed within the article that an extended evaluation of the PolarCap® System is adopted by all teams in the two biggest professional rugby leagues in France, the Top14 and Pro D2, to evaluate the treatment provided by the PolarCap® System on a large scale.
PolarCool’s CEO Erik Andersson comments;
– The international attention that PolarCap® System now gets is very positive. The article also describes the positive feedback from the users being very content with the treatment. This feedback is also well aligned with the trend that we see regarding those who have started using the PolarCap® System wanting to continue.
The Le Parisien feature serves as an impactful exposure for the PolarCap® System and will contribute to PolarCool’s continual momentum in securing sports partnerships in France and beyond.
For more information
Erik Andersson – CEO PolarCool AB (publ)
+46 – 738 60 57 00
E-mail: erik.andersson@polarcool.se
About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.